IMS Capital购买了Gilead的股份,收入丰厚,并提出了指导意见。 IMS Capital bought Gilead shares amid strong earnings and raised guidance.

2025年,IMS资本管理公司购买了2 028份Gilead Science(GILD)股份,价值约225 000美元。 IMS Capital Management bought 2,028 shares of Gilead Sciences (GILD) for about $225,000 in Q2 2025. 该公司报告Q2收入丰厚,EPS为2.01美元,收入为70.8亿美元,超过估计。 The company reported strong Q2 earnings with $2.01 EPS and $7.08 billion in revenue, exceeding estimates. Gilead将其2025年EPS指南提高到7.95美元至8.25美元,并维持了“Moderate Buy”共识,目标是117.17美元。 Gilead raised its 2025 EPS guidance to $7.95–$8.25 and maintains a “Moderate Buy” consensus with a $117.17 target. 2025年9月25日的股票交易额为113.67美元,股息收益为2.8%,市场上限为141.04亿美元。 The stock traded at $113.67 on September 25, 2025, with a 2.8% dividend yield and a market cap of $141.04 billion. 主要产品包括用于艾滋病毒、肝炎和COVID-19的Biktarvy、Epclusa和Veklury。 Key products include Biktarvy, Epclusa, and Veklury, used for HIV, hepatitis, and COVID-19. 机构所有权占83.67%,近几个月内内部出售的股份总额近140万美元。 Institutional ownership is 83.67%, and insiders sold shares totaling nearly $1.4 million in recent months.